8-K: DaVita Reports Strong Q4, Full-Year 2025 Results

DaVita Inc. announced strong financial and operating results for the fourth quarter and full year ended December 31, 2025, meeting financial targets despite a challenging environment.

Summary

• Consolidated revenues were $3.620 billion for the three months ended December 31, 2025, and $13.643 billion for the full year.
• Adjusted operating income reached $586 million for the fourth quarter and $2,094 million for the full year 2025.
• Adjusted diluted earnings per share from continuing operations was $3.40 for the fourth quarter and $10.78 for the full year 2025.
• Operating cash flow was $541 million for the fourth quarter and $1,887 million for the full year 2025.
• Free cash flow amounted to $309 million for the fourth quarter and $1,024 million for the full year 2025.
• Repurchased 2.7 million shares of common stock for $331 million at an average price of $122.78 per share in the fourth quarter of 2025.
• Repurchased 12.7 million shares for $1.788 billion at an average price of $140.09 per share for the full year 2025.
• Refinanced existing Term Loan A-1 and revolving line of credit in November 2025 with a new $2.0 billion Term Loan A-2 and a $1.5 billion revolving line of credit.
• Incurred $20.5 million in impairment and restructuring charges related to the Mozarc Medical Holding LLC equity investment, partially offset by a $12.6 million gain on remeasurement of contingent consideration.
• Total U.S. dialysis treatments for the fourth quarter of 2025 were 7,264,520, representing a per day decrease of (0.1)% compared to the third quarter of 2025.
• Normalized non-acquired treatment growth in the fourth quarter of 2025 compared to the fourth quarter of 2024 was (0.6)%.
• Revenue per treatment increased by $12.01 quarter-over-quarter to $422.60 and by $18.24 year-over-year to $409.56.
• Patient care costs per treatment increased by $6.06 quarter-over-quarter to $279.60 and by $15.22 year-over-year to $273.34.
• As of December 31, 2025, provided dialysis services to approximately 295,000 patients at 3,242 outpatient dialysis centers globally.
• Approximately 66,000 patients were in risk-based integrated care arrangements, representing an estimated $5.6 billion in annualized medical spend.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a solid performance, meeting internal targets and demonstrating financial stability through debt refinancing and share repurchases, despite some headwinds in treatment volume and increased costs.

Positives

• Consolidated revenues increased to $3.620 billion for Q4 2025 and $13.643 billion for the full year 2025.
• Adjusted operating income for the full year 2025 increased to $2,094 million from $1,981 million in 2024.
• Adjusted diluted EPS from continuing operations for the full year 2025 increased to $10.78 from $9.68 in 2024.
• Repurchased 12.7 million shares of common stock for $1.788 billion in 2025, demonstrating commitment to shareholder returns.
• Successfully refinanced existing Term Loan A-1 and revolving line of credit, enhancing capital structure.
• Revenue per treatment increased by $12.01 quarter-over-quarter to $422.60 and by $18.24 year-over-year to $409.56, driven by reimbursement rates and mix.
• Integrated Kidney Care (IKC) patients in risk-based arrangements grew to approximately 66,000, representing $5.6 billion in annualized medical spend.

Negatives

• U.S. dialysis treatments per day decreased by (0.1)% compared to the third quarter of 2025.
• Normalized non-acquired treatment growth in Q4 2025 was (0.6)% compared to Q4 2024.
• Operating cash flow for the full year 2025 decreased to $1,887 million from $2,022 million in 2024.
• Free cash flow for the full year 2025 decreased to $1,024 million from $1,162 million in 2024.
• Net income attributable to DaVita Inc. for the full year 2025 decreased to $746.8 million from $936.3 million in 2024.
• Diluted EPS from continuing operations for the full year 2025 decreased to $9.51 from $10.73 in 2024.
• Incurred $20.5 million in impairment and restructuring charges related to the Mozarc investment.
• Patient care costs per treatment increased by $15.22 year-to-date to $273.34, primarily due to increased pharmaceutical costs, compensation, medical supply, and health benefit expenses.
• General and administrative expenses increased by $79 million year-to-date, driven by IT-related costs and costs related to a cybersecurity incident.

Risks

• External conditions, including general economic, political, and global health conditions, and the impact of global events and political or governmental volatility.
• The impact of the domestic political environment and related developments on the current healthcare marketplace, patients, and business, including policy initiatives and potential government shutdowns.
• The continuing impact of infectious diseases on the chronic kidney disease population and patient population.
• Supply chain challenges and disruptions, including with key services, critical clinical supplies, and equipment, and any impacts on the supply chain and cost of supplies as a result of natural disasters or evolving trade policies, including tariffs.
• The potential impact on patients and industry of new or potential entrants in the dialysis and pre-dialysis marketplace and innovative technologies, drugs, or other treatments.
• Elevated teammate turnover or labor costs.
• The impact of continued increased competition from dialysis providers and others.
• Ability to respond to challenging U.S. and global economic and marketplace conditions, including identifying cost saving opportunities.
• The concentration of profits generated by higher-paying commercial payor plans for which there is continued downward pressure on average realized payment rates.
• Ability to negotiate and maintain contracts with payors on competitive terms or at all.
• A reduction in the number or percentage of patients under commercial plans, including as a result of healthcare, immigration, or other policies, legislative efforts to restrict or prohibit charitable premium assistance, or restrictive plan designs.
• Risks arising from laws, regulations, or requirements applicable or changes thereto, including the One Big Beautiful Bill Act (OBBBA) and those related to trade policy, healthcare, privacy, antitrust matters, and labor matters.
• Ability to successfully implement strategic and operational initiatives in a complex, evolving, and highly regulated environment, including with respect to Integrated Kidney Care (IKC) and Value-Based Care (VBC) initiatives and home-based dialysis.
• A reduction in government payment rates under the Medicare End Stage Renal Disease program, state Medicaid, or other government-based programs and the impact of the Medicare Advantage (MA) benchmark structure and adjustment methodologies.
• Reliance on significant suppliers, service providers, and other third-party vendors to provide key support to business operations and enable the provision of services to patients.
• Ability to successfully maintain, operate, or upgrade information systems or those of third-party service providers and ability to successfully adopt or adapt to new technologies, treatments, or therapies.
• Legal and compliance risks, such as compliance with complex, and at times, evolving government regulations and requirements, and with additional laws that may apply as operations expand geographically or enter new lines of business.
• Noncompliance by the company or business associates with any privacy or security laws or any security breach by the company or a third party, such as the cybersecurity incident experienced in 2025.
• Ability to attract, retain, and motivate teammates, including key leadership personnel, and ability to manage potential disruptions to business and operations, including potential work stoppages, operating cost increases, or productivity decreases.
• Changes in practice patterns related to pharmaceuticals, medical equipment or supplies, reimbursement and payment policies and processes, or pricing, including with respect to oral phosphate binders.
• Ability to develop and maintain relationships with physicians and hospitals, changing affiliation models for physicians, and the emergence of new models of care or other initiatives that may erode the patient base and impact reimbursement rates.
• Ability to complete and successfully integrate and operate acquisitions, mergers, dispositions, joint ventures, or other strategic transactions on terms favorable or at all.
• Ability to continue to successfully expand operations and services in markets outside the United States, or to businesses or products outside of dialysis services.
• The variability of cash flows, including any extended billing or collections cycles due to defects or operational issues in billing systems, the impact of the cybersecurity incident experienced in 2025, or defects in third-party billing systems.
• The risk that the company may not be able to generate or access sufficient cash in the future to service indebtedness or to fund other liquidity needs.
• The effects of natural or other disasters, public health crises, or severe adverse weather events such as hurricanes, earthquakes, fires, or flooding.
• Factors that may impact the ability to repurchase stock under the share repurchase program and the timing of any such stock repurchases, as well as any use of a considerable amount of available funds to repurchase stock.
• Goals and disclosures related to sustainability matters, including evolving regulatory requirements affecting environmental, social, and governance standards, measurements, and reporting requirements.

Future Outlook

For 2026, DaVita projects adjusted operating income between $2,085 million and $2,235 million, and adjusted diluted net income from continuing operations per share between $13.60 and $15.00. Free cash flow is expected to range from $1,000 million to $1,250 million. Normalized treatment days for 2026 are projected to be 312.4, a slight decrease from 313.2 in 2025.

Management Comments

• "Our strong platform delivered once again in 2025, providing high quality, innovative care to our patients and achieving the financial targets we set out at the beginning of the year despite a challenging environment." Javier Rodriguez, CEO of DaVita.
• "Given our ongoing investments and process improvements, we are confident in our ability to continue to deliver both clinically and financially in 2026 and beyond." Javier Rodriguez, CEO of DaVita.

Industry Context

StockSavvy.ai notes that DaVita's focus on Integrated Kidney Care (IKC) and value-based care (VBC) arrangements aligns with broader healthcare industry trends towards preventative care, chronic disease management, and cost-efficiency. The slight decline in U.S. dialysis treatment volume per day, coupled with increased patient care costs, reflects ongoing challenges in the traditional dialysis market, including potential shifts in patient populations or care models. The company's debt refinancing and share repurchase activities indicate a focus on capital structure optimization and shareholder returns, common strategies among mature healthcare providers.

Stakeholder Impact

• Shareholders are positively impacted by strong financial results, significant share repurchases, and a stable outlook.
• Patients continue to receive high-quality, innovative care, with an expansion of integrated kidney care arrangements.
• Employees (teammates) face increased compensation expenses, and the company acknowledges risks related to teammate turnover and labor costs.
• Creditors benefit from active debt management, including successful refinancing, which maintains access to capital.
• Suppliers are impacted by increased medical supply costs, and the company's reliance on significant suppliers is noted as a risk factor.

Next Steps

• A conference call to discuss results for the fourth quarter ended December 31, 2025, will be held on February 2, 2026, at 5:00 p.m. Eastern Time.
• Ongoing investments and process improvements are planned to continue delivering clinically and financially in 2026 and beyond.
• The company will continue to execute on its capital allocation plans and strategic initiatives, including its share repurchase program.

Key Dates

Recommendation

DaVita delivered expected results, met its financial targets, and demonstrated prudent capital management through debt refinancing and share repurchases. However, the slight decline in U.S. dialysis treatment volume and increased patient care costs present ongoing operational challenges. The 2026 guidance is generally in line with expectations, suggesting a stable but not rapidly accelerating growth trajectory. For a seasoned investor, these factors suggest a 'hold' position, awaiting clearer signs of sustained volume growth or significant margin expansion.

Keywords

DaVita, DVA, Dialysis, Kidney Care, Financial Results, Q4 2025, Full Year 2025, Earnings, Revenue, Operating Income, EPS, Cash Flow, Share Repurchase, Debt Refinancing, Integrated Kidney Care, US Dialysis, Patient Volume, Reimbursement Rates, SEC Filing, 8-K